1-Propanamine,3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl- cas no:72-69-5
Synonyms: 5H-Dibenzo[a,d]cycloheptene-D5,g-propylamine, 10,11-dihydro-N-methyl- (8CI);10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptane-Dgpropylamine;3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropylamine;5-[3-(Methylamino)propylidene]dibenzo[a,e]cyclohepta[1,5]diene;Ateben;Avantyl;Aventyl;Demethylamitriptyline;Desitriptilina;Lumbeck;NCI 169453;Nortriptyline;Sesaval;
Name1-Propanamine,3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-
CAS72-69-5
Synonyms5H-Dibenzo[a,d]cycloheptene-D5,g-propylamine, 10,11-dihydro-N-methyl- (8CI);10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptane-Dgpropylamine;3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropylamine;5-[3-(Methylamino)propylidene]dibenzo[a,e]cyclohepta[1,5]diene;Ateben;Avantyl;Aventyl;Demethylamitriptyline;Desitriptilina;Lumbeck;NCI 169453;Nortriptyline;Sesaval;
EINECS(EC#)200-788-8
Molecular FormulaC19H21N
Molecular Weight263.41
refractive index1.633
Safety
Poison by ingestion, intraperitoneal, and intravenous routes. When heated to decomposition it emits toxic fumes of NOx.
| Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
| mouse |
LD50 |
intraperitoneal |
70mg/kg (70mg/kg) |
|
Journal of Medicinal Chemistry. Vol. 6, Pg. 338, 1963. |
| mouse |
LD50 |
intravenous |
17mg/kg (17mg/kg) |
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) |
Journal of Medicinal Chemistry. Vol. 17, Pg. 65, 1974. |
| mouse |
LD50 |
oral |
370mg/kg (370mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1561, 1970. |
| rat |
LD50 |
intravenous |
22mg/kg (22mg/kg) |
BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: ATAXIA
BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) |
Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980. |
| rat |
LD50 |
oral |
502mg/kg (502mg/kg) |
BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: ATAXIA
BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) |
Handbook of Experimental Pharmacology. Vol. 55, Pg. 527, 1980. |
| women |
TDLo |
oral |
160mg/kg (160mg/kg) |
BEHAVIORAL: COMA
VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE |
Journal of Toxicology, Clinical Toxicology. Vol. 37, Pg. 634, 1999. |
